BRAINIAC Hub Targets Earlier Dementia Detection Through AI and NHS Clinics
A new multi-million pound research hub is aiming to change how dementia is detected, assessed and followed over time by combining artificial intelligence with brain imaging, genetics, blood biomarkers and digital cognitive testing. The BRAINIAC Hub, led by the University of Exeter, is funded with £10 million from the Engineering and Physical Sciences Research Council, with another £10 million coming from industry, charity and NHS partners. The project is built around a simple clinical problem with enormous consequences: people are still arriving too late for the diagnosis to alter the course of care in a meaningful way.
The hub will run for six years, with the first clinics scheduled to begin operating in 2029 and initially open through NHS referral. Its stated aim is to create a single, clearer picture of brain health by integrating data streams that are usually considered separately in routine practice. In practical terms, that means the system will look beyond memory complaints and attempt to identify biological change before symptoms become obvious, when preventive action has a better chance of slowing decline.
One sentence captures the clinical ambition plainly: the goal is to cut the time to diagnosis in half.
A Single Brain Health Picture from Multiple Data Streams
BRAINIAC stands for AI and Emerging Technologies for Next Generation Brain Health Clinics, and it brings together 11 universities and 10 NHS sites. The hub is designed to create one of the largest research platforms in the UK focused on what actually improves diagnosis, prevention and treatment for dementia. Rather than relying on a single test, the model combines several sources of information: structural and functional brain imaging, inherited risk markers, blood-based biomarkers and digital cognitive assessments. The logic is straightforward. Dementia rarely starts with one isolated abnormality; it emerges through interacting changes in brain structure, vascular health, metabolism and neurodegeneration, and AI is being asked to find patterns too complex for a clinician to assemble in a standard appointment.
David Llewellyn, who directs BRAINIAC and is professor of clinical epidemiology and digital health at the University of Exeter Medical School, described detection as the hardest problem. His point reflects a daily neurology reality: by the time dementia is obvious enough to label confidently, the underlying pathology has often been evolving for years. Early detection matters because current therapies and support services work best when introduced before substantial functional loss has already occurred.
The hub’s clinics are intended to help identify more than 40% of the people they assess as being at early risk before symptoms develop. That ambition is paired with a broader aim to reduce risk for patients and shorten the route from first concern to diagnosis.
Why Earlier Diagnosis Changes the Care Pathway
Dementia is not a single disease, but a syndrome with multiple causes, including Alzheimer’s disease, vascular injury and mixed pathology. In each case, the earlier the process is identified, the more time there is to address modifiable risk factors, manage comorbidities and plan care with patients and families while capacity remains intact. AI-driven triage could be particularly valuable in busy NHS settings, where specialist services often face high demand and long waits.
BRAINIAC’s stated targets are unusually concrete for a research program. UK Research and Innovation has committed up to £80 million for researchers developing tools that could help diagnose 92% of people referred with suspected dementia within 18 weeks by 2029. The hub also aims to make assessment and diagnosis 30% to 50% faster. These goals speak to the real bottleneck in memory services: not just finding disease, but moving people through the pathway quickly enough for the answer to matter.
The pressure on that pathway is only set to grow. About 982,000 people in the UK live with dementia, and the number is projected to reach 1.4 million by 2040. Annual cost is expected to rise to more than £90 billion. Those figures translate into clinic waiting lists, caregiver strain, loss of independence and a heavy burden on community and hospital services. Any system that can reliably triage risk earlier, especially one built into NHS referral pathways, has the potential to reduce avoidable delay at multiple points in care.
Designed for Real Clinics, Not Just Research Papers
Chris Fox, BRAINIAC deputy director and professor of clinical psychiatry at the University of Exeter Medical School, said current treatments only help if people are diagnosed early. That is the central tension in dementia care: disease-modifying strategies, symptom management and support services all depend on finding the right patients before the window for benefit narrows further.
Fox also stressed that the tools are being designed with patients and clinicians from the start so they work in a busy clinic rather than only on paper. That design principle matters because digital health systems often fail at the bedside when they add complexity without saving time. A platform that can assemble an interpretable risk profile from several tests may help clinicians separate people who need urgent specialist review from those who can be monitored more conservatively. In a service under pressure, that kind of sorting function can matter as much as the technology itself.
The hub’s approach also reflects a broader shift in neuroscience and psychiatry toward earlier, biology-based diagnosis. Blood biomarkers and imaging are increasingly used to move away from symptom-only classification, especially when cognitive symptoms are subtle, fluctuating or confounded by depression, sleep disturbance, sensory loss or medication effects. Combining those measures with machine learning could improve consistency, although the clinical value will depend on whether predictions are accurate, interpretable and practical enough to use at scale.
Scale, Partnership and the Limits of the Next Step
BRAINIAC is one of five new hubs funded across the UK, and the wider program includes a mix of universities, NHS sites and partner organisations such as Dementia UK and the Alzheimer’s Society. The university described the project as part of a broader push to translate research into clinical benefit, alongside earlier hub work that included the world’s first AI-assisted brain tumour surgery.
Charlotte Deane, executive chair of the Engineering and Physical Sciences Research Council at UKRI, said the hubs are intended to improve lives by moving cutting-edge research into healthcare delivery. For dementia, the immediate test will not be whether the system can generate sophisticated risk scores, but whether those scores improve referral quality, shorten diagnostic delays and support decisions clinicians can trust.
The unanswered questions are operational rather than abstract. Can AI-based clinics preserve accuracy across different NHS settings? Will the combined data model remain reliable when used outside a research cohort? And can early-risk identification be scaled without overwhelming already stretched memory services? The project is designed to answer those questions over six years, with clinics due to begin in 2029. Until then, the clearest signal is the one built into the funding itself: dementia diagnosis is still too slow, and the next phase of care will depend on making detection far earlier than it is today.